Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?

被引：10
|
作者：
Goldenberg, Ronald M. [1 ]
Verma, Subodh [2 ]
Perkins, Bruce A. [3 ]
Gilbert, Jeremy D. [4 ]
Zinman, Bernard [5 ]
机构：
[1] LMC Diabet & Endocrinol, Thornhill, ON, Canada
[2] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Dept Surg,Div Cardiac Surg, Toronto, ON, Canada
[3] Univ Toronto, Mt Sinai Hosp, Dept Med, Div Endocrinol & Metab, Toronto, ON, Canada
[4] Sunnybrook Hlth Sci Ctr, Div Endocrinol & Metab, Toronto, ON, Canada
[5] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
来源：
CANADIAN JOURNAL OF DIABETES | 2017年 / 41卷 / 01期
关键词：
TYPE-2; DIABETES-MELLITUS; PANCREATIC ALPHA-CELLS; DAPAGLIFLOZIN ADD-ON; DOUBLE-BLIND; POSTPRANDIAL GLUCAGON; BETA-CELLS; METFORMIN; THERAPY; SAXAGLIPTIN; SECRETION;
D O I：
10.1016/j.jcjd.2016.08.001
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6 / 9
页数：4
相关论文
共 50 条
  • [31] Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications
    Alejandrina M. Castañeda
    Amanda Dutra-Rufato
    Maria J. Juarez
    Luis Grosembacher
    Henry Gonzalez-Torres
    Carlos G. Musso
    International Urology and Nephrology, 2021, 53 : 291 - 299
  • [32] Eligibility and Response to Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Therapy How Useful Are Cardiac Biomarkers?
    Echouffo-Tcheugui, Justin B.
    Selvin, Elizabeth
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (05) : 445 - 447
  • [33] Hepatic expression of sodium-glucose cotransporter 2 (SGLT2) in patients with chronic liver disease
    Nakano, Dan
    Akiba, Jun
    Tsutsumi, Tsubasa
    Kawaguchi, Machiko
    Yoshida, Takafumi
    Koga, Hironori
    Kawaguchi, Takumi
    MEDICAL MOLECULAR MORPHOLOGY, 2022, 55 (04) : 304 - 315
  • [34] Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
    Fediuk, Daryl J.
    Nucci, Gianluca
    Dawra, Vikas Kumar
    Cutler, David L.
    Amin, Neeta B.
    Terra, Steven G.
    Boyd, Rebecca A.
    Krishna, Rajesh
    Sahasrabudhe, Vaishali
    CLINICAL PHARMACOKINETICS, 2020, 59 (08) : 949 - 965
  • [35] Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
    Daryl J. Fediuk
    Gianluca Nucci
    Vikas Kumar Dawra
    David L. Cutler
    Neeta B. Amin
    Steven G. Terra
    Rebecca A. Boyd
    Rajesh Krishna
    Vaishali Sahasrabudhe
    Clinical Pharmacokinetics, 2020, 59 : 949 - 965
  • [36] THE POTENTIAL ROLE OF SODIUM/GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS IN THE TREATMENT OF CYSTINURIA
    Sui, Wilson
    Yang, Heiko
    Desai, Manoj
    Chi, Thomas
    Stoller, Marshall
    JOURNAL OF UROLOGY, 2024, 211 (05): : E421 - E421
  • [37] Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications
    Castaneda, Alejandrina M.
    Dutra-Rufato, Amanda
    Juarez, Maria J.
    Grosembacher, Luis
    Gonzalez-Torres, Henry
    Musso, Carlos G.
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2021, 53 (02) : 291 - 299
  • [38] Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective
    Madaan, Tushar
    Akhtar, Mohd.
    Najmi, Abul Kalam
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 93 : 244 - 252
  • [39] Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
    Mahling, Moritz
    Schork, Anja
    Nadalin, Silvio
    Fritsche, Andreas
    Heyne, Nils
    Guthoff, Martina
    KIDNEY & BLOOD PRESSURE RESEARCH, 2019, 44 (05): : 984 - 992
  • [40] Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
    Abdul-Ghani, Muhammad A.
    Norton, Luke
    DeFronzo, Ralph A.
    ENDOCRINE REVIEWS, 2011, 32 (04) : 515 - 531
12345